Carcinomas: Work with pancreatic cancer (PANCS) supports the concept that KDM6A normally acts as a tumour suppressor, since ablation of KDM6A can lead to development of PANCS in a mouse model, and in patients, oncogenes are activated in females and in males with UTY loss [78]. This evidence concerns the gene KDM6A and carcinoma.